Dec 23, 2019
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Dec 05, 2019
Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting
Dec 05, 2019
Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home
Nov 28, 2019
The global apheresis equipment market is expected to reach US$ 3,528.44 Mn in 2027 from US$ 1,985.83 Mn in 2018
Nov 21, 2019
LightIntegra Technology appoints new board member
Nov 20, 2019
Haemonetics Releases TEG® 6s PlateletMapping® ADP & AA Assay Cartridge Globally
Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Oct 28, 2019
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Oct 09, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Sep 19, 2019
Instrumentation Laboratory Launches HemosIL® AcuStar ADAMTS13 Activity Assay In Europe And Other International Markets*
Sep 16, 2019
China Prothrombin Complex Concentrate Market to 2023: Disease Incidences, Supply/Demand, Competition, Prices, Market Prospects
Sep 04, 2019
Instrumentation Laboratory Awarded Point-of-Care Coagulation/Patient Blood Management Agreement With Premier
Aug 06, 2019
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Jul 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Jul 08, 2019
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
Jul 03, 2019
Easing the Burden for People with Hemophilia
Jul 01, 2019
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Jun 26, 2019
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019